Pivotal readout
Xanamem Misses Primary Endpoint
The 247-person XanaMIA trial missed its primary endpoint: Xanamem's 0.10-point CDR-SB advantage over placebo at week 36 was not statistically significant (p=0.65). Among participants older than 75, 40% receiving Xanamem had no CDR-SB progression versus 22% on placebo (p=0.02); the subgroup's mean CDR-SB difference was not statistically significant (p=0.22).
No serious adverse events were attributed to Xanamem. Actinogen plans further analysis and discussions with potential partners and the FDA.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.